舌下变应原免疫疗法治疗儿童支气管哮喘伴变应性鼻炎的临床评价

发布时间：2019-04-03 15:47

【摘要】：目的探讨舌下变应原特异性免疫疗法(SLIT)治疗支气管哮喘伴变应性鼻炎的疗效及安全性。方法选取5~14岁的哮喘伴变应性鼻炎患儿120例,随机分成SLIT治疗组(舌下含服粉尘螨滴剂)和常规治疗组,每组60例。记录两组患儿治疗前后哮喘控制问卷(ACQ)评分、鼻炎症状评分、月均用药情况和不良反应,检测血清粉尘螨特异性IgE(SIgE)值。结果治疗1年后,SLIT治疗组和常规治疗组的ACQ评分、鼻炎症状评分、治疗哮喘月均用药评分及血清粉尘螨SIgE值均有所下降,且SLIT治疗组下降程度明显高于常规治疗组,差异有统计学意义(P0.01)。SLIT治疗组与用药相关的皮疹、鼻咽痒和哮喘发作不良反应发生率为13.3%,未出现严重不良反应。结论 SLIT治疗儿童哮喘伴变应性鼻炎安全有效,比常规治疗效果更佳。
[Abstract]:Objective to evaluate the efficacy and safety of sublingual allergen specific immunotherapy (SLIT) in the treatment of bronchial asthma with allergic rhinitis. Methods one hundred and twenty children with asthma with allergic rhinitis aged 5-14 years were randomly divided into two groups: SLIT treatment group (sublingual administration of dust mite drops) and routine treatment group (60 cases in each group). The asthma control questionnaire (ACQ) score, rhinitis symptom score, monthly drug use and adverse reaction were recorded before and after treatment in the two groups. The serum specific IgE (SIgE) value of Dermatophagoides farinae was detected. Results after 1 year's treatment, the ACQ score, rhinitis symptom score, monthly drug score and serum SIgE value in SLIT group and routine treatment group were all decreased, and the degree of decrease in SLIT treatment group was significantly higher than that in routine treatment group, and the degree of decrease in SLIT treatment group was significantly higher than that in routine treatment group. Slitt treatment group with drug-related rash, nasopharynx itching and asthma attack adverse reaction rate was 13.3%, no serious adverse reaction. Conclusion SLIT is safe and effective in the treatment of asthma with allergic rhinitis in children, and it is more effective than routine therapy.
【作者单位】：复旦大学附属中山医院青浦分院儿科;复旦大学附属中山医院青浦分院检验科;复旦大学附属儿科医院呼吸科;
【分类号】：R725.6;R765.21

【参考文献】